Personalized tamoxifen: What is the best way forward?

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3206-3208

  Rae, James M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN(4 HYDROXY N DESMETHYL TAMOXIFEN); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN BCL 2; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER HORMONE THERAPY; DISEASE MARKER; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; EDITORIAL; FEMALE; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; HUMANS; TAMOXIFEN;

EID: 80051995856     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.3895     Document Type: Editorial

References (23)

1. Berry D.A., Cronin K.A., Plevritis S.K., et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005 (Pubitemid 41549890)
2. Dowsett M., Cuzick J., Ingle J., et al: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
4. McGuire W.L.: Current status of estrogen receptors in human breast cancer. Cancer 36:638-644, 1975
5. Hatzis C., Pusztai L., Valero V., et al: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305:1873-1881, 2011
6. Dowsett M., Allred C., Knox J., et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
7. Wang L., McLeod H.L., Weinshilboum R.M.: Genomics and drug response. N Engl J Med 364:1144-1153, 2011
8. Stearns V., Johnson M.D., Rae J.M., et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003 (Pubitemid 38008898)
9. Borges S., Desta Z., Li L., et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006 (Pubitemid 43946844)
10. Goetz M.P., Rae J.M., Suman V.J., et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
11. Hayes D.F., Stearns V., Rae J., et al: A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst 100:610-613, 2008
12. Holmes F.A., Liticker J.D.: Pharmacogenomics of tamoxifen in a nutshell-and who broke the nutcracker? J Oncol Pract 1:155-159, 2005
13. Goetz M.P., Kamal A., Ames M.M.: Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83:160-166, 2008
14. Phan M.T., Venitz J: Summary Minutes of the Advisory Committee Pharmaceutical Science Clinical Pharmacology Subcommittee. Rockville, MD, Center for Drug Evaluation and Research Advisory Committee, 2006. http://www.fda.gov/ ohrms/dockets/ac/06/minutes/2006-4248m1.pdf
15. Medco Health Solutions: CYp2D6 testing for tamoxifen. http://www.medcohealth.com/medco/corporate/home.jsp?ltSess=y&articleID= CorpPM-Tamoxifen
16. Lash T.L., Rosenberg C.L.: Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol 28:1273-1275, 2010
17. Simon R.M., Paik S., Hayes D.F.: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
18. Irvin W.J. Jr, Walko C.M., Weck K.E., et al: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 29:3232-3239, 2011
19. De Grann A-JM, Teunissen S.F., De Vos F.Y.F.L., et al: Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 29:3240-3246, 2011
20. Rae J.M., Drury S., Hayes D.F., et al: Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-12, 2010 (abstr S1-7)
21. Leyland-Jones B., Regan M.M., Bouzyk M., et al: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1098 Trial. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-12, 2010 (abstr S1-8)
22. Ingle J.N., Buzdar A.U., Schaid D.J., et al: Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 70:3278-3286, 2010
23. Ingle JN: Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: Going beyond associations. Breast Cancer Res 12:S17, 2010 (suppl 4)